Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 12,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) insider Joseph P. Lyssikatos sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $18.60, for a total value of $223,200.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Joseph P. Lyssikatos also recently made the following trade(s):

  • On Thursday, February 29th, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.42, for a total transaction of $197,040.00.
  • On Monday, January 29th, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.85, for a total transaction of $190,200.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $18.59 on Thursday. The company’s fifty day moving average is $16.22 and its two-hundred day moving average is $13.91. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $23.98.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds have recently added to or reduced their stakes in ELVN. Vanguard Group Inc. grew its holdings in Enliven Therapeutics by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 1,230,888 shares of the company’s stock valued at $17,035,000 after buying an additional 79,071 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Enliven Therapeutics by 28.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 22,698 shares of the company’s stock worth $314,000 after purchasing an additional 5,008 shares during the last quarter. Barclays PLC grew its holdings in shares of Enliven Therapeutics by 208.7% during the fourth quarter. Barclays PLC now owns 42,078 shares of the company’s stock worth $583,000 after buying an additional 28,449 shares in the last quarter. Citadel Advisors LLC raised its position in shares of Enliven Therapeutics by 1.8% in the fourth quarter. Citadel Advisors LLC now owns 2,394,448 shares of the company’s stock valued at $33,139,000 after buying an additional 42,782 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Enliven Therapeutics by 69.8% during the fourth quarter. Royal Bank of Canada now owns 7,991 shares of the company’s stock valued at $110,000 after buying an additional 3,284 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

See Also

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.